Pappone Carlo, Santinelli Vincenzo
Dipartimento di Aritmologia, Maria Cecilia Hospital, GVM Care and Research, Cotignola, Rávena, Italy.
Rev Esp Cardiol (Engl Ed). 2012 Jun;65(6):560-9. doi: 10.1016/j.recesp.2011.12.023. Epub 2012 Apr 26.
Atrial fibrillation is the commonest cardiac arrhythmia, with significant morbidity related to symptoms, heart failure, and thromboembolism, which is associated with excess mortality. Over the past 10 years, many centers worldwide have reported high success rates and few complications after a single ablation procedure in patients with paroxysmal atrial fibrillation. Recent studies indicate a short-term and long-term superiority of catheter ablation as compared with conventional antiarrhythmic drug therapy in terms of arrhythmia recurrence, quality of life, and arrhythmia progression. As a result, catheter ablation is evolving to a front-line therapy in many patients with atrial fibrillation. However, in patients with persistent long-standing atrial fibrillation catheter ablation strategy is more complex and time-consuming, frequently requiring repeat procedures to achieve success rates as high as in paroxysmal atrial fibrillation. In the near future, however, with growing experience and evolving technology, catheter ablation of atrial fibrillation may be extended also to patients with long-standing atrial fibrillation.
心房颤动是最常见的心律失常,其发病率与症状、心力衰竭及血栓栓塞相关,后者会增加死亡率。在过去10年里,全球许多中心报告称,阵发性心房颤动患者单次消融手术后成功率高且并发症少。最近的研究表明,与传统抗心律失常药物治疗相比,导管消融在心律失常复发、生活质量及心律失常进展方面具有短期和长期优势。因此,导管消融正逐渐成为许多心房颤动患者的一线治疗方法。然而,对于持续性长期心房颤动患者,导管消融策略更为复杂且耗时,通常需要重复手术才能达到与阵发性心房颤动患者一样高的成功率。不过在不久的将来,随着经验的积累和技术的发展,心房颤动的导管消融可能也会应用于长期心房颤动患者。